If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
While negotiating with Alpachi for the hostages' release, Umeko realizes the truth and clears his name, while her teammates rescue Alpachi's son and delete Goldom. Attika Alpachi is voiced by Bin Shimada. Shinnooian Hakutaku (シンノー星人ハクタク, Shinnō Seijin Hakutaku): A wise woman from Planet Shinoo, with knowledge of all space herbs, who occasionally assumes the form of a human teenage girl and possesses a third eye shaped like a red jewel. After the Dekarangers take her into their protective custody, she provides guidance to Sen-chan, becomes attracted to him, and raises money for their wedding. Hakutaku is voiced by Reiko Suzuki (鈴木 れい子, Suzuki Reiko) while her human form is portrayed by Narumi Konno (近野 成美, Kon'no Narumi). Bandarean Jeeva (バンダレ星人ジーバ, Bandare Seijin Jība): A physically imposing Oni-themed alien, and champion boxer in Durden's illegal fight club, from Planet Bandare. After consuming Durden's steroid, Megagesterine, and gaining wing-like horns on his arms and neck, Jeeva fights Hoji, who defeats him. Following this, Jeeva reformed and found work as the assistant director of a television station. Jeeva is voiced by Toshitsugu Takashina (高階 俊嗣, Takashina Toshitsugu). Slorpean Faraway (スロープ星人ファラウェイ, Surōpu Seijin Farawei): A small-time criminal from Planet Slorpe who resembles a ganguro girl and possesses proficient hacking skills.
== Pharmacokinetics == Endogenous GLP-1 has a plasma half-life of 1.5–2 minutes due to degradation by the ubiquitous enzymes, dipeptidyl peptidase-4 (DPP4) and neutral endopeptidases (NEP). The half-life after intramuscular injection is approximately half an hour, so even administered this way, it has limited use as a therapeutic agent. The metabolically active forms of GLP-1 are the endogenous GLP-1-(7-36)NH2 and the more rare GLP-1-(7-37). The prolonged action of liraglutide is achieved by attaching a fatty acid molecule at one position of the GLP-1-(7-37) molecule, enabling it to both self-associate and bind to albumin within the subcutaneous tissue and bloodstream. The active GLP-1 is then released from albumin at a slow, consistent rate. Albumin binding also results in slower degradation and reduced renal elimination compared to that of GLP-1-(7-37).
These species feature elements from groups I, II, III, IV, V, VI, VII, 0 (excluding hydrogen) of the periodic table. Due to their often similar reactivity, the elements in group 3 (Sc, Y, and La) and group 12 (Zn, Cd, and Hg) are also generally included, and the lanthanides and actinides are sometimes included as well. Main group compounds have been known since the beginnings of chemistry, e.g., elemental sulfur and the distillable white phosphorus. Experiments on oxygen, O2, by Lavoisier and Priestley not only identified an important diatomic gas, but opened the way for describing compounds and reactions according to stoichiometric ratios. The discovery of a practical synthesis of ammonia using iron catalysts by Carl Bosch and Fritz Haber in the early 1900s deeply impacted mankind, demonstrating the significance of inorganic chemical synthesis. Typical main group compounds are SiO2, SnCl4, and N2O. Many main group compounds can also be classed as "organometallic", as they contain organic groups, e.g., B(CH3)3. Main group compounds also occur in nature, e.g., phosphate in DNA, and therefore may be classed as bioinorganic. Conversely, organic compounds lacking (many) hydrogen ligands can be classed as "inorganic", such as the fullerenes, buckytubes and binary carbon oxides.
Sources: en.wikipedia.org
== Mechanisms == There is no single theory covering adhesion, and particular mechanisms are specific to particular material scenarios. Five mechanisms of adhesion have been proposed to explain why one material sticks to another:
==== Chinese, Korean, and Japanese-language ==== A 2010 systematic review of the Chinese-language literature found numerous acupuncture-related adverse events, including pneumothorax, fainting, subarachnoid hemorrhage, and infection as the most frequent, and cardiovascular injuries, subarachnoid hemorrhage, pneumothorax, and recurrent cerebral hemorrhage as the most serious, most of which were due to improper technique. Between 1980 and 2009, the Chinese-language literature reported 479 adverse events. Prospective surveys show that mild, transient acupuncture-associated adverse events ranged from 6.71% to 15%. In a study with 190,924 patients, the prevalence of serious adverse events was roughly 0.024%. Another study showed a rate of adverse events requiring specific treatment of 2.2%, 4,963 incidences among 229,230 patients. Infections, mainly hepatitis, after acupuncture are reported often in English-language research, though are rarely reported in Chinese-language research, making it plausible that acupuncture-associated infections have been underreported in China. Infections were mostly caused by poor sterilization of acupuncture needles.
== Ecological status == In 1998, the International Union for Conservation of Nature warned that one of the primary frankincense species, Boswellia sacra, is "near threatened". Frankincense trees are not covered by the Convention on International Trade in Endangered Species of Wild Fauna and Flora, but experts argue that Boswellia species meet the criteria for protection. In a 2006 study, an ecologist at Wageningen University & Research claimed that, by the late-1990s, Boswellia papyrifera trees in Eritrea were becoming hard to find. In 2019, a new paper predicted a 50% reduction in Boswellia papyrifera within the next two decades. This species, found mainly in Ethiopia, Eritrea, and Sudan, accounts for about two-thirds of global frankincense production. The paper warns that all Boswellia species are threatened by habitat loss and overexploitation. Most Boswellia grow in harsh, arid regions beset by poverty and conflict. Harvesting and selling the tree's resin is one of the few sources of income for the inhabitants, resulting in overtapping.
== Further reading == Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH (June 2001). "Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate". Fertil. Steril. 75 (6): 1065–79. doi:10.1016/S0015-0282(01)01791-5. PMID 11384629.{{cite journal}}: CS1 maint: multiple names: authors list (link) (the Women's Health, Osteoporosis, Progestin, Estrogen study) Hulley S, Grady D, Bush T, et al. (August 1998). "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group". JAMA. 280 (7): 605–13. doi:10.1001/jama.280.7.605. PMID 9718051.
Sources: en.wikipedia.org
== Clinical relevance == Pyruvate dehydrogenase deficiency (PDCD) can result from mutations in any of the enzymes or cofactors used to build the complex. Its primary clinical finding is lactic acidosis. Such PDCD mutations, leading to subsequent deficiencies in NAD and FAD production, hinder oxidative phosphorylation processes that are key in aerobic respiration. Thus, acetyl-CoA is instead reduced via anaerobic mechanisms into other molecules like lactate, leading to an excess of bodily lactate and associated neurological pathologies. While pyruvate dehydrogenase deficiency is rare, there are a variety of different genes when mutated or nonfunctional that can induce this deficiency. First, the E1 subunit of pyruvate dehydrogenase contains four different subunits: two alpha subunits designated as E1-alpha and two beta subunits designated as E1-beta. The PDHA1 gene found in the E1-alpha subunits, when mutated, causes 80% of the cases of pyruvate dehydrogenase deficiency because this mutation abridges the E1-alpha protein. Decreased functional E1 alpha prevents pyruvate dehydrogenase from sufficiently binding to pyruvate, thus reducing the activity of the overall complex. When the PDHB gene found in the E1 beta subunit of the complex is mutated, this also leads to pyruvate dehydrogenase deficiency.
Loxapine, sold under the brand names Loxitane and Adasuve (inhalation only) among others, is a tricyclic antipsychotic medication used primarily in the treatment of schizophrenia and bipolar disorder. It is a member of the dibenzoxazepine class and structurally very similar to clozapine. Several researchers have argued that loxapine, initially classified as a typical antipsychotic, behaves as an atypical antipsychotic. Loxapine may be metabolized by N-demethylation to amoxapine, a tricyclic antidepressant.
=== The Activation of Photo-Methionine === Because the previous synthesis had worked, photo-methionine is photo-reactive due to the diazirine ring. Once this ring has become exposed to UV light, nitrogen leaves as nitrogen gas (N2) and forms the highly reactive intermediate carbene. Photo-activation of amino acids provide the ability of photo-cross-linking in proteins. This type of cross-linking has three major advantages; there is greater specificity for this cross linking due to the short lived intermediates and that this amino acid is functional, and most importantly; not toxic (meaning it should not disrupt the protein's function or structure dramatically). Research had found that this activation is the rate-limiting step; not the cross-linkage.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.